472 related articles for article (PubMed ID: 31587590)
41. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence.
Rizzo A; Rosellini M; Marchetti A; Mollica V; Massari F
Immunotherapy; 2021 Jun; 13(8):685-692. PubMed ID: 33823678
[TBL] [Abstract][Full Text] [Related]
42. Developments in personalized therapy for metastatic renal cell carcinoma.
Fujiwara R; Kageyama S; Yuasa T
Expert Rev Anticancer Ther; 2022 Jun; 22(6):647-655. PubMed ID: 35531636
[TBL] [Abstract][Full Text] [Related]
43. Pembrolizumab for the treatment of renal cell carcinoma.
Di Bona C; Stühler V; Rausch S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Sep; 21(9):1157-1164. PubMed ID: 34042015
[TBL] [Abstract][Full Text] [Related]
44. Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma.
Stühler V; Rausch S; Maas JM; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Sep; 21(9):1215-1226. PubMed ID: 33576709
[TBL] [Abstract][Full Text] [Related]
45. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
[TBL] [Abstract][Full Text] [Related]
46. Recent advances and future directions in the management of metastatic renal cell carcinoma.
Ansari J; Glaholm J; McMenemin R; James ND; Hussain SA
Anticancer Agents Med Chem; 2010 Mar; 10(3):225-35. PubMed ID: 20184547
[TBL] [Abstract][Full Text] [Related]
47. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
[TBL] [Abstract][Full Text] [Related]
48. The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.
Huang JJ; Hsieh JJ
Semin Nephrol; 2020 Jan; 40(1):28-41. PubMed ID: 32130964
[TBL] [Abstract][Full Text] [Related]
49. Recent pharmacological approaches for the treatment of renal cell carcinoma.
Alimohammadi A; Fajkovic H; Remzi M; Shariat S; Schmidinger M
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):187-195. PubMed ID: 35285369
[TBL] [Abstract][Full Text] [Related]
50. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
[TBL] [Abstract][Full Text] [Related]
51. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.
Gurram S; Al Harthy M; Ball MW
Discov Med; 2020; 29(158):191-199. PubMed ID: 33007194
[TBL] [Abstract][Full Text] [Related]
52. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
[TBL] [Abstract][Full Text] [Related]
53. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Epaillard N; Simonaggio A; Elaidi R; Azzouz F; Braychenko E; Thibault C; Sun CM; Moreira M; Oudard S; Vano YA
Bull Cancer; 2020 Jun; 107(5S):eS22-eS27. PubMed ID: 32620212
[TBL] [Abstract][Full Text] [Related]
54. Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - A retrospective study.
Jammal N; Pan E; Hurwitz M; Abramovitz RB
J Oncol Pharm Pract; 2020 Apr; 26(3):556-563. PubMed ID: 31216241
[TBL] [Abstract][Full Text] [Related]
55. Immunotherapy for kidney cancer: status quo and the future.
Bedke J; Stühler V; Stenzl A; Brehmer B
Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911
[TBL] [Abstract][Full Text] [Related]
56. To be or not to be: whether anti-angiogenic agent combined with immune checkpoint inhibitoris necessary in the treatment of advanced or metastatic renal cell carcinoma.
Sun L; Zhang L; Yu J; Zhou Y; Shi C; Wasan HS; Ruan S; Huang D
Med Oncol; 2020 Feb; 37(2):15. PubMed ID: 32008152
[TBL] [Abstract][Full Text] [Related]
57. Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient.
Borchiellini D; Maillet D
Bull Cancer; 2022 May; 109(2S):2S4-2S18. PubMed ID: 35760470
[TBL] [Abstract][Full Text] [Related]
58. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
59. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
Rini BI; Battle D; Figlin RA; George DJ; Hammers H; Hutson T; Jonasch E; Joseph RW; McDermott DF; Motzer RJ; Pal SK; Pantuck AJ; Quinn DI; Seery V; Voss MH; Wood CG; Wood LS; Atkins MB
J Immunother Cancer; 2019 Dec; 7(1):354. PubMed ID: 31856918
[TBL] [Abstract][Full Text] [Related]
60. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]